Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.
Antipsychotic Agents
/ therapeutic use
Aripiprazole
/ therapeutic use
Butyrophenones
/ therapeutic use
Chlorpromazine
Dopamine
/ metabolism
Dopamine Agonists
/ therapeutic use
Histamine
Humans
Psychotic Disorders
/ drug therapy
Railroads
Receptors, Dopamine D2
/ metabolism
Systematic Reviews as Topic
Antipsychotics
classification
dopamine
drugs for psychosis
psychopharmacology
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
2
9
2022
medline:
28
9
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
Drugs used to treat psychotic disorders ('antipsychotics') have been widely used in psychiatry since the introduction of chlorpromazine in the mid-1950s. The categorization of these drugs evolved in a piecemeal way, relying initially on grouping by chemical structure (e.g. phenothiazines, butyrophenones), then by epoch of introduction (e.g. first generation ('conventional') vs second generation ('atypical')). As psychopharmacological expertise has advanced, it has become possible to quantify affinities for each drug in this class for relevant receptors including dopamine D2, 5HT2A, 5HT2C, histamine H1 and others. However, until the recent emergence of a new generation of agents known collectively as dopamine D2 receptor partial agonists (e.g. aripiprazole, brexpiprazole and cariprazine), there had been little reference in drug classification to specific pharmacological properties. An overview of data on receptor affinities across multiple drugs and receptor types would permit categorization according to binding affinities and putative pharmacological mechanisms. In this paper, we have attempted to construct a 'subway map' of 32 drugs used for treatment of psychotic disorders. This design allows a visualization of both the historical classifications by structure and epoch of introduction, and of the binding affinities for key receptors based on appraisal of scientific literature. The map represents a step towards categorization by mechanism, allowing prescribers and patients to understand which drugs share common biological features and the extent to which drugs may have similarities and differences in their mechanisms. In addition, this approach may encourage more logical groupings of drugs to be used in systematic reviews and meta-analyses.
Identifiants
pubmed: 36045588
doi: 10.1177/02698811221115758
pmc: PMC9516596
doi:
Substances chimiques
Antipsychotic Agents
0
Butyrophenones
0
Dopamine Agonists
0
Receptors, Dopamine D2
0
Histamine
820484N8I3
Aripiprazole
82VFR53I78
Chlorpromazine
U42B7VYA4P
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1007-1015Références
Pharmacol Res. 1999 Aug;40(2):165-70
pubmed: 10433876
Expert Opin Drug Saf. 2016 Sep;15(9):1193-203
pubmed: 27207070
Pharmacol Ther. 1995 May;66(2):339-68
pubmed: 7667401
Innov Clin Neurosci. 2018 Feb 1;15(1-2):16-22
pubmed: 29497575
Pharmacol Ther. 2018 Dec;192:20-41
pubmed: 29953902
Science. 1975 Jun 20;188(4194):1217-9
pubmed: 1145194
Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12
pubmed: 27525990
J Pharmacol Exp Ther. 2014 Sep;350(3):589-604
pubmed: 24947465
Neuropsychiatr Dis Treat. 2013;9:587-94
pubmed: 23766647
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81
pubmed: 20404009
Life Sci. 1984 Apr 16;34(16):1529-40
pubmed: 6144029
Front Neurosci. 2019 Dec 06;13:1309
pubmed: 31866817
J Psychopharmacol. 2009 Jun;23(4):343-5
pubmed: 19433474
Neuropharmacology. 2018 Jul 1;136(Pt C):438-448
pubmed: 28893562
Eur Neuropsychopharmacol. 2014 Jul;24(7):1005-14
pubmed: 24630385
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1145-58
pubmed: 14642973